A novel lead compound CM-118: Antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers

Cancer Biology and Therapy

Volumn 15, Issue 6, 2014, Pages 721-734

  Meng, Lanfang ^a   Shu, Mengjun ^b   Chen, Yaqing ^a   Yang, Dexiao ^c   He, Qun ^a   Zhao, Hui ^a   Feng, Zhiyong ^c   Liang, Chris ^d   Yu, Ker ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c Sundia MediTech Company   (China)

^d Xcovery Inc   (United States)

Author keywords

ALK; c Met; Combination therapy; EGFR; mTOR; Targeted cancer therapy

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AZD 8055; BIM PROTEIN; CM 118; CRIZOTINIB; CYCLIN D1; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RAPAMYCIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; CM-118; EGFR PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PYRIDAZINE DERIVATIVE; PYRIDONE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GLIOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SINGLE DRUG DOSE; STOMACH TUMOR; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; IC50; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; GLIOMA; HUMANS; INHIBITORY CONCENTRATION 50; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MET; PYRIDAZINES; PYRIDONES; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898625749     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28409     Document Type: Article

References (44)

1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172-87; PMID:16014887; http://dx.doi.org/10.1056/ NEJMra044389
2. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006; 3:448-57; PMID:16894390; http://dx.doi.org/10.1038/ncponc0558
3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, et al.; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004; PMID:12637609; http://dx.doi.org/10.1056/NEJMoa022457
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/ NEJM200103153441101
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 2005; 353:123-32; PMID:16014882; http://dx.doi.org/10.1056/NEJMoa050753
6. Morales La Madrid A, Campbell N, Smith S, Cohn SL, Salgia R. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol 2012; 7:199-210; PMID:22968692; http://dx.doi.org/10.1007/s11523-012-0227-8
7. Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov 2011; 10:897-8; PMID:22129984; http://dx.doi.org/10.1038/nrd3600
8. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-703; PMID:20979469; http://dx.doi.org/10.1056/NEJMoa1006448
9. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-6; PMID:17625570; http://dx.doi.org/10.1038/nature05945
10. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131:1190-203; PMID:18083107; http://dx.doi.org/10.1016/j.cell.2007.11.025
11. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263:1281-4; PMID:8122112; http://dx.doi.org/10.1126/science.8122112
12. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999; 59:2776-80; PMID:10383129
13. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455:930-5; PMID:18724359; http://dx.doi.org/10.1038/nature07261
14. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455:967-70; PMID:18923523; http://dx.doi.org/10.1038/nature07398
15. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455:971-4; PMID:18923524; http://dx.doi.org/10.1038/ nature07399
16. George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455:975-8; PMID:18923525; http://dx.doi.org/10.1038/nature07397
17. Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008; 416:153-9; PMID:18990089; http://dx.doi.org/10.1042/BJ20081834
18. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6:3314-22; PMID:18089725; http://dx.doi.org/10.1158/1535-7163.MCT-07-0365
19. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12:89-103; PMID:22270953; http://dx.doi.org/10.1038/nrc3205
20. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012; 9:314-26; PMID:22566105; http://dx.doi.org/10.1038/ nrclinonc.2012.71
21. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18:2343-50; PMID:10327054; http://dx.doi.org/10.1038/sj.onc.1202547
22. Soman NR, Correa P, Ruiz BA, Wogan GN. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A 1991; 88:4892-6; PMID:2052572; http://dx.doi.org/10.1073/pnas.88.11.4892
23. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43; PMID:17463250; http://dx.doi.org/10.1126/science.1141478
24. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17:77-88; PMID:20129249; http://dx.doi.org/10.1016/j.ccr.2009.11.022
25. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-9; PMID:19249681; http://dx.doi.org/10.1016/j.ccr.2009.01.021
26. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012; 2:270-87; PMID:22585997; http://dx.doi.org/10.1158/2159-8290.CD-11-0240
27. Sennino B, Ishiguro-Oonuma T, Schriver BJ, Christensen JG, McDonald DM. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res 2013; 73:3692-703; PMID:23576559; http://dx.doi.org/10.1158/0008- 5472.CAN-12-2160
28. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALKdriven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011; 71:4920-31; PMID:21613408; http://dx.doi.org/10.1158/0008-5472.CAN-10-3879
29. Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011; 3:108ra114; PMID:22072639; http://dx.doi.org/10.1126/ scitranslmed.3002950
30. Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011; 17:7394-401; PMID:21948233; http://dx.doi.org/10.1158/1078-0432.CCR-11- 1648
31. Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 2008; 9:1336-46; PMID:19037840
32. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70:288-98; PMID:20028854; http://dx.doi.org/10.1158/0008-5472.CAN-09-1751
33. McMahon LP, Choi KM, Lin TA, Abraham RT, Lawrence JC Jr. The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol Cell Biol 2002; 22:7428-38; PMID:12370290; http://dx.doi.org/10.1128/MCB.22.21.7428-7438.2002
34. Paglin S, Lee NY, Nakar C, Fitzgerald M, Plotkin J, Deuel B, Hackett N, McMahill M, Sphicas E, Lampen N, et al. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res 2005; 65:11061-70; PMID:16322256; http://dx.doi.org/10.1158/ 0008-5472.CAN-05-1083
35. Kinoshita K, Oikawa N, Tsukuda T. Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers. Annu Rep Med Chem 2012; 47:281-93; http://dx.doi.org/10.1016/B978-0-12-396492-2.00019-9
36. Liu X, Newton RC, Scherle PA. Development of c-MET pathway inhibitors. Expert Opin Investig Drugs 2011; 20:1225-41; PMID:21740293; http://dx.doi.org/ 10.1517/13543784.2011.600687
37. Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 2012; 11:1557-64; PMID:22729845; http://dx.doi.org/10.1158/1535-7163.MCT-11-0934
38. Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H, Nakagawa K. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 2011; 6:1624-31; PMID:21716144; http://dx.doi.org/ 10.1097/JTO.0b013e31822591e9
39. Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008; 105:692-7; PMID:18180459; http://dx.doi.org/10.1073/pnas.0707270105
40. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011; 30:3625-35; PMID:21423210; http://dx.doi.org/10.1038/onc.2011.84
41. Zhang YW, Staal B, Essenburg C, Lewis S, Kaufman D, Vande Woude GF. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther 2013; 12:1429-41; PMID:23720767; http://dx.doi.org/10.1158/1535-7163.MCT-13-0016
42. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009; 69:6232-40; PMID:19584280; http://dx.doi.org/10. 1158/0008-5472.CAN-09-0299
43. Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 2008; 7:307-15; PMID:18059185; http://dx.doi.org/10.4161/cbt.7.2.5334
44. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010; 70:621-31; PMID:20068177; http://dx.doi.org/10.1158/0008-5472.CAN-09-2340